Merck Serono identifies UK as personalised meds laggard
This article was originally published in Scrip
Executive Summary
Makers of personalised cancer medicines trying to sell their products in the UK may be fighting a losing battle. A survey compiled by Merck Serono found that 75% of oncologists believe there are barriers preventing the use of personalised medicines within the UK's National Health Service.